Terumo Cardiovascular Group

e-mail usprint

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

ABSTRACT: Intraoperative Treatment Strategy to Reduce the Incidence of Post-Cardiopulmonary Bypass Atrial Fibrillation. Perfusion 2002; V 17. O-Yurvati A.
In this study, the authors demonstrate a 72% reduction in the incidence of post-op atrial fibrillation in patients who receive leukocyte filtration and aprotinin, resulting in $8,725 savings per patient.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: Clinical Evaluation of a Leuko-Depleting Blood Cardioplegia Filter (BC1B) for Elective Open-Heart Surgery. Perfusion 1998; 13: 205-210. Suzuki, et al.
In this study of 40 CABG patients, the authors demonstrate the ability of the Pall BC1 filter to remove inflammatory mediators CPK-MB and troponin.

ABSTRACT: The Role of Leukocyte Depleting Filters in Heart Transplantation: Early Outcomes in Prospective, Randomized Clinical Trial. European Journal of Cardiothoracic Surgery. October 2006; 30: 621-627. Dvorak, et al.
In this study of 40 patients, the authors find leukocyte filtration reduces markers of reperfusion injury, time on ventilation and time in the ICU, and improves graft functionality.